Fig. 5: Combined SRSF1 constructs validate the splicing phenotype after Cfz. | Nature Communications

Fig. 5: Combined SRSF1 constructs validate the splicing phenotype after Cfz.

From: Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

Fig. 5

a Histograms of ΔPSI in pooled analysis of parental AMO−1-, SRSF1-WT-, SD-, and SA-expressing cells treated with 15 nM Cfz compared to DMSO. b Graph shows total number of events (n = 62,474) for each ASE type (left panel) and only the significant (FDR-corrected p < 0.05) events (n = 2,575) for each type (right panel). c Top ranked GO enrichment terms of all genes involved in significant ASEs, regardless of type. d RNA-seq coverage map (UCSC Genome Browser) compares counts for the proteasomal subunit PSMC5 between AMO-1 treated with 15 nM Cfz (bottom panel) and with DMSO (top panel). Inset displays sequencing counts showing alternative first exon. e Model of new PI mechanism of action found in MM.

Back to article page